Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Collyar: What's In It for Patients?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Dec

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Collyar: What's In It for Patients?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups

Outcomes Associated With Consensus Molecular Subtypes in First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer

Addition of Pirfenidone to Glucocorticoids in Grade 2 or 3 Radiation-Induced Lung Injury

Lung Cancer Screening Criteria NELSON vs PLCOm2012

ADCs vs Standard Chemotherapy: Cardiotoxicity in HER2-Positive Advanced Breast Cancer